Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations

Jane Ahlqvist-Rastad; Maria Albertsson; Jonas Bergh; Gunnar Birgegard; Peter Johansson; Bertil Jonsson; Elisabeth Kjellén; Sven Pahlman; Bjorn Zackrisson; Anders Osterborg

doi:10.1007/s12032-007-0037-5

Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations

Jane Ahlqvist-Rastad, Maria Albertsson, Jonas Bergh, Gunnar Birgegard, Peter Johansson, Bertil Jonsson, Elisabeth Kjellén, Sven Pahlman, Bjorn Zackrisson, Anders Osterborg

Breastcancer-genetics

Research output: Contribution to journal › Article › peer-review

Abstract

Due to concerns related to treatment with erythropoietin (EPO) and possible negative effects on tumour control, a workshop was organised by the Medical Products Agency of Sweden with the aim to revise national treatment guidelines if needed. In patients with solid tumours, conflicting results have been reported with respect to tumour control and survival. Until further notice it is therefore recommended that EPO should be used restrictively in the treatment of patients with cancer and that the anticipated improvement in quality of life should be evaluated against potential risks.

Original language	English
Pages (from-to)	267-272
Journal	Medical Oncology
Volume	24
Issue number	3
DOIs	https://doi.org/10.1007/s12032-007-0037-5
Publication status	Published - 2007

Subject classification (UKÄ)

Cancer and Oncology

Free keywords

erythropoietin
safety
cancer therapy
epoetin
anemia
receptor

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12032-007-0037-5

http://humanapress.com/index.php?option=com_journalshome&task=articledetails&category=journals&article_code=MO:24:3:267

Cite this

@article{1f09295cbded48ca9f6c9d9bbbeaa107,

title = "Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations",

abstract = "Due to concerns related to treatment with erythropoietin (EPO) and possible negative effects on tumour control, a workshop was organised by the Medical Products Agency of Sweden with the aim to revise national treatment guidelines if needed. In patients with solid tumours, conflicting results have been reported with respect to tumour control and survival. Until further notice it is therefore recommended that EPO should be used restrictively in the treatment of patients with cancer and that the anticipated improvement in quality of life should be evaluated against potential risks.",

keywords = "erythropoietin, safety, cancer therapy, epoetin, anemia, receptor",

author = "Jane Ahlqvist-Rastad and Maria Albertsson and Jonas Bergh and Gunnar Birgegard and Peter Johansson and Bertil Jonsson and Elisabeth Kjell{\'e}n and Sven Pahlman and Bjorn Zackrisson and Anders Osterborg",

year = "2007",

doi = "10.1007/s12032-007-0037-5",

language = "English",

volume = "24",

pages = "267--272",

journal = "Medical Oncology",

issn = "1559-131X",

publisher = "Humana Press",

number = "3",

}

TY - JOUR

T1 - Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations

AU - Ahlqvist-Rastad, Jane

AU - Albertsson, Maria

AU - Bergh, Jonas

AU - Birgegard, Gunnar

AU - Johansson, Peter

AU - Jonsson, Bertil

AU - Kjellén, Elisabeth

AU - Pahlman, Sven

AU - Zackrisson, Bjorn

AU - Osterborg, Anders

PY - 2007

Y1 - 2007

N2 - Due to concerns related to treatment with erythropoietin (EPO) and possible negative effects on tumour control, a workshop was organised by the Medical Products Agency of Sweden with the aim to revise national treatment guidelines if needed. In patients with solid tumours, conflicting results have been reported with respect to tumour control and survival. Until further notice it is therefore recommended that EPO should be used restrictively in the treatment of patients with cancer and that the anticipated improvement in quality of life should be evaluated against potential risks.

AB - Due to concerns related to treatment with erythropoietin (EPO) and possible negative effects on tumour control, a workshop was organised by the Medical Products Agency of Sweden with the aim to revise national treatment guidelines if needed. In patients with solid tumours, conflicting results have been reported with respect to tumour control and survival. Until further notice it is therefore recommended that EPO should be used restrictively in the treatment of patients with cancer and that the anticipated improvement in quality of life should be evaluated against potential risks.

KW - erythropoietin

KW - safety

KW - cancer therapy

KW - epoetin

KW - anemia

KW - receptor

U2 - 10.1007/s12032-007-0037-5

DO - 10.1007/s12032-007-0037-5

M3 - Article

SN - 1559-131X

VL - 24

SP - 267

EP - 272

JO - Medical Oncology

JF - Medical Oncology

IS - 3

ER -

Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations

Abstract

Subject classification (UKÄ)

Free keywords

UN SDGs

Access to Document

Fingerprint

Cite this